Research Analysts Offer Predictions for HURA FY2026 Earnings

TuHURA Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

TuHURA Biosciences, Inc. (NASDAQ:HURA - Free Report) - Equities research analysts at HC Wainwright upped their FY2026 EPS estimates for TuHURA Biosciences in a research note issued on Tuesday, November 17th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.46) per share for the year, up from their prior forecast of ($0.55). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for TuHURA Biosciences' current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for TuHURA Biosciences' Q4 2026 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.10) EPS and FY2027 earnings at ($0.39) EPS.

A number of other brokerages have also recently weighed in on HURA. Weiss Ratings restated a "sell (e+)" rating on shares of TuHURA Biosciences in a report on Thursday, October 15th. Citizens Jmp reiterated a "market outperform" rating and set a $9.00 target price on shares of TuHURA Biosciences in a report on Tuesday, August 18th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.50.

Read Our Latest Stock Report on TuHURA Biosciences

TuHURA Biosciences Trading Down 2.1%

NASDAQ HURA opened at $1.37 on Thursday. The firm has a 50 day simple moving average of $1.88 and a 200-day simple moving average of $2.01. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.18 and a current ratio of 0.47. TuHURA Biosciences has a one year low of $0.41 and a one year high of $3.43. The firm has a market cap of $90.09 million, a price-to-earnings ratio of -2.74 and a beta of -0.23.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.04.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Two Sigma Securities LLC acquired a new stake in shares of TuHURA Biosciences during the 2nd quarter worth about $33,000. Merck & Co. Inc. lifted its stake in TuHURA Biosciences by 39.4% during the first quarter. Merck & Co. Inc. now owns 19,445 shares of the company's stock worth $35,000 after purchasing an additional 5,495 shares during the last quarter. Sanctuary Advisors LLC purchased a new stake in TuHURA Biosciences during the second quarter worth approximately $49,000. Deutsche Bank AG purchased a new stake in TuHURA Biosciences during the second quarter worth approximately $52,000. Finally, Hsbc Holdings PLC acquired a new position in TuHURA Biosciences in the second quarter valued at approximately $69,000. 0.62% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about TuHURA Biosciences

These are some of the HURA headlines that stood out recently:

  • Positive Sentiment: HC Wainwright raised its 2026 and 2027 EPS forecasts, including improving its FY2027 estimate to a loss of $0.39 per share from $0.61, and reaffirmed its Buy rating. Brookline also lifted several forecasts, including FY2029 to $0.05 per share and FY2030 to $0.48. Less-negative estimates and a projected longer-term move to profitability may support investor sentiment. TuHURA analyst estimates
  • Neutral Sentiment: The reports concern analyst forecasts rather than new company results or a clinical, regulatory, or commercial development, so they do not confirm that earnings will improve as projected. HC Wainwright Buy rating
  • Negative Sentiment: Despite the favorable revisions, the supplied market data places HURA below its 50-day and 200-day moving averages, indicating ongoing share-price weakness that could temper the positive analyst news.

TuHURA Biosciences Company Profile

(Get Free Report)

TuHURA Biosciences is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research focuses on treatments intended to stimulate the immune system and address mechanisms that allow tumors to evade immune attack. The company's pipeline includes IFx-2.0, an investigational intratumoral immunotherapy being studied for use with checkpoint inhibitors, as well as antibody programs targeting immune-regulating pathways. TuHURA has no marketed products, and its candidates remain in development.

Featured Articles

Earnings History and Estimates for TuHURA Biosciences (NASDAQ:HURA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in TuHURA Biosciences Right Now?

Before you consider TuHURA Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.

While TuHURA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines